Artificial Intelligence For Drug Development and Discovery Market by Type (Target Identification, Molecule Screening, De Novo Drug Design & Drug Optimization, and Preclinical & Clinical Testing), Indication, (Oncology, Neurology, Infectious Disease and Others), and End User (Pharmaceutical & Biotechnology Companies, and Contract Research Organization): Global Opportunity Analysis and Industry Forecast, 2019–2027

1.1. Report description

1.1. Key benefits for stakeholders

1.2. Key market segments

1.2.1. List of key players profiled in the report

1.3. Research methodology

1.3.1. Secondary research

1.3.2. Primary research

1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top investment pockets

3.2.2. Top winning strategies

3.3. Top player positioning, 2019

3.4. Porter’s five forces analysis

3.5. Market dynamics

3.5.1. Drivers

3.5.1.1. Growing number of cross industry collaborations and partnerships

3.5.1.2. Artificial intelligence reduces cost and time utilized in the drug discovery& development process.

3.5.2. Restraints

3.5.2.1. Lack of skilled professionals

3.5.2.2. Lack of data sets in the field of drug discovery

3.5.3. Opportunity

3.5.3.1. Increase in awareness related to artificial intelligence

3.5.3.2. Untapped market in developing regions

3.5.4. Impact Analysis

CHAPTER 4: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Target Identification

4.2.1. Key market trends, growth factors, and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market analysis, by country

4.3. Molecule Screening

4.3.1. Key market trends, growth factors, and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market analysis, by country

4.4. De Novo Drug Design and Drug Optimization

4.4.1. Key market trends, growth factors, and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market analysis, by country

4.5. Preclinical and clinical testing

4.5.1. Key market trends, growth factors, and opportunities

4.5.2. Market size and forecast, by region

4.5.3. Market analysis, by country

CHAPTER 5: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, BY INDICATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Oncology

5.2.1. Market size and forecast, by region

5.2.2. Market analysis, by country

5.3. Neurology

5.3.1. Market size and forecast, by region

5.3.2. Market analysis, by country

5.4. Infectious Disease

5.4.1. Market size and forecast, by region

5.4.2. Market analysis, by country

5.5. Others

5.5.1. Market size and forecast, by region

5.5.2. Market analysis, by country

CHAPTER 6: ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Pharmaceutical and biotechnology companies

6.2.1. Market size and forecast, by region

6.2.2. Market analysis, by country

6.3. Contract Research Organization

6.3.1. Market size and forecast, by region

6.3.2. Market analysis, by country

CHAPTER 7: GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors, and opportunities

7.2.2. North America artificial intelligence for drug discovery and development , by country

7.2.2.1. U.S.

7.2.2.1.1. U.S. artificial intelligence for drug discovery and development market, by type

7.2.2.1.2. U.S artificial intelligence for drug discovery and development market, by indication

7.2.2.1.3. U.S. artificial intelligence for drug discovery and development market, by end user

7.2.2.2. Canada

7.2.2.2.1. Canada artificial intelligence for drug discovery and development market, by type

7.2.2.2.2. Canada artificial intelligence for drug discovery and development market, by indication

7.2.2.2.3. Canada artificial intelligence for drug discovery and development market, by end user

7.2.3. North America artificial intelligence for drug discovery and development market, by type

7.2.4. North America artificial intelligence for drug discovery and development , by indication

7.2.5. North America artificial intelligence for drug discovery and development , by end user

7.3. Europe

7.3.1. Key market trends, growth factors, and opportunities

7.3.2. Europe artificial intelligence for drug discovery and development , by country

7.3.2.1. UK artificial intelligence for drug discovery and development market, by type

7.3.2.1.1. UK artificial intelligence for drug discovery and development market, by type

7.3.2.1.2. UK artificial intelligence for drug discovery and development market, by indication

7.3.2.1.3. UK artificial intelligence for drug discovery and development market, by end user

7.3.2.2. Germany

7.3.2.2.1. Germany artificial intelligence for drug discovery and development market, by type

7.3.2.2.2. Germany artificial intelligence for drug discovery and development market, by indication

7.3.2.2.3. Germany artificial intelligence for drug discovery and development market, by end user

7.3.2.3. France

7.3.2.3.1. France artificial intelligence for drug discovery and development market, by type

7.3.2.3.2. France artificial intelligence for drug discovery and development market, by indication

7.3.2.3.3. France artificial intelligence for drug discovery and development market, by end user

7.3.2.4. Rest of Europe

7.3.2.4.1. Rest of Europe artificial intelligence for drug discovery and development market, by type

7.3.2.4.2. Rest of Europe artificial intelligence for drug discovery and development market, by indication

7.3.2.4.3. Rest of Europe artificial intelligence for drug discovery and development market, by end user

7.3.3. Europe artificial intelligence for drug discovery and development , by type

7.3.4. Europe artificial intelligence for drug discovery and development , by indication

7.3.5. Europe artificial intelligence for drug discovery and development , by end user

7.4. Asia-pacific

7.4.1. Key market trends, growth factors, and opportunities

7.4.2. Asia-Pacific artificial intelligence for drug discovery and development , by country

7.4.2.1. Japan

7.4.2.1.1. Japan artificial intelligence for drug discovery and development market, by type

7.4.2.1.2. Japan artificial intelligence for drug discovery and development market, by indication

7.4.2.1.3. Japan artificial intelligence for drug discovery and development market, by end user

7.4.2.2. China

7.4.2.2.1. China artificial intelligence for drug discovery and development market, by type

7.4.2.2.2. China artificial intelligence for drug discovery and development market, by indication

7.4.2.2.3. China artificial intelligence for drug discovery and development market, by end user

7.4.2.3. Australia

7.4.2.3.1. .Australia artificial intelligence for drug discovery and development market, by type

7.4.2.3.2. Australia artificial intelligence for drug discovery and development market, by indication

7.4.2.3.3. Australia artificial intelligence for drug discovery and development market, by end user

7.4.2.4. India

7.4.2.4.1. India artificial intelligence for drug discovery and development market, by type

7.4.2.4.2. India artificial intelligence for drug discovery and development market, by indication

7.4.2.4.3. India artificial intelligence for drug discovery and development market, by end user

7.4.2.5. Rest of Asia-Pacific

7.4.2.5.1. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by type

7.4.2.5.2. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by indication

7.4.2.5.3. Rest of Asia-Pacific artificial intelligence for drug discovery and development market, by end user

7.4.3. Asia-Pacific artificial intelligence for drug discovery and development , by type

7.4.4. Asia-Pacific artificial intelligence for drug discovery and development , by indication

7.4.5. Asia-Pacific artificial intelligence for drug discovery and development , by end user

7.5. LAMEA

7.5.1. Key market trends, growth factors, and opportunities

7.5.2. LAMEA artificial intelligence for drug discovery and development , by country

7.5.2.1. Latin America

7.5.2.1.1. Latin America artificial intelligence for drug discovery and development market, by type

7.5.2.1.2. Latin America artificial intelligence for drug discovery and development market, by indication

7.5.2.1.3. Latin America artificial intelligence for drug discovery and development market, by end user

7.5.2.2. Middle east and Africa

7.5.2.2.1. Middle east and Africa artificial intelligence for drug discovery and development market, by type

7.5.2.2.2. Middle east and Africa artificial intelligence for drug discovery and development market, by indication

7.5.2.2.3. Middle east and Africa artificial intelligence for drug discovery and development market, by end user

CHAPTER 8: COMPANY PROFILES

8.1. ALPHABET INC.

8.1.1. Company overview

8.1.2. Company snapshot

8.1.3. Operating business segments

8.1.4. Product portfolio

8.1.5. Business performance

8.2. ATOMWISE, INC.

8.2.1. Company overview

8.2.2. Company snapshot

8.2.3. Operating business segment

8.2.4. Product portfolio

8.2.5. Key strategic moves and developments

8.3. BENEVOLENT AI

8.3.1. Company overview

8.3.2. Company snapshot

8.3.3. Operating business segment

8.3.4. Product portfolio

8.3.5. Key strategic moves and developments

8.4. CLOUD PHARMACEUTICAL

8.4.1. Company overview

8.4.2. Company snapshot

8.4.3. Operating business segment

8.4.4. Product portfolio

8.4.5. Key strategic moves and developments

8.5. DEEP GENOMICS

8.5.1. Company overview

8.5.2. Company snapshot

8.5.3. Operating business segment

8.5.4. Product portfolio

8.6. EXSCIENTIA.

8.6.1. Company overview

8.6.2. Company snapshot

8.6.3. Operating business segment

8.6.4. Product portfolio

8.6.5. Key strategic moves and developments

8.7. IBM CORPORATION

8.7.1. Company overview

8.7.2. Company snapshot

8.7.3. Operating business segments

8.7.4. Product portfolio

8.7.5. Business performance

8.7.6. Key strategic moves and developments

8.8. INSILICO MEDICINE INC.

8.8.1. Company overview

8.8.2. Company snapshot

8.8.3. Operating business segment

8.8.4. Product portfolio

8.8.5. Key strategic moves and developments

8.9. MICROSOFT CORPORATION

8.9.1. Company overview

8.9.2. Company snapshot

8.9.3. Operating business segments

8.9.4. Product portfolio

8.9.5. Business performance

8.9.6. Key strategic moves and developments

8.10. NVIDIA CORPORATION

8.10.1. Company overview

8.10.2. Company snapshot

8.10.3. Operating business segments

8.10.4. Product portfolio

8.10.5. Business performance

TABLE 01. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET, BY TYPE, 2019–2027 ($MILLION)

TABLE 02. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FORTARGET IDENTIFICATION, BY REGION, 2019–2027 ($MILLION)

TABLE 03. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FOR MOLECULE SCREENING, BY REGION, 2019–2027 ($MILLION)

TABLE 04. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FORDE NOVO DRUG DESIGN AND DRUG OPTIMIZATION, BY REGION, 2019–2027 ($MILLION)

TABLE 05. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY & DEVELOPMENT MARKET FOR DE NOVO DRUG DESIGN AND DRUG OPTIMIZATION, BY REGION, 2019–2027 ($MILLION)

TABLE 06. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET, BY INDICATION, 2019–2027($MILLION)

TABLE 07. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY ONCOLOGY, 2019–2027 ($MILLION)

TABLE 08. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY NEUROLOGY, 2019–2027 ($MILLION)

TABLE 09. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY INFECTIOUS DISEASE, 2019–2027 ($MILLION)

TABLE 10. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENTMARKET REVENUE, BY OTHERS, 2019–2027 ($MILLION)

TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2019–2027 ($MILLION)

TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, 2019–2027 ($MILLION)

TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY CONTRACT RESEARCH ORGANIZATION, 2019–2027 ($MILLION)

TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)

TABLE 15. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)

TABLE 16. U.S. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 17. U.S. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 18. U.S. ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT, BY END USER, 2019-2027 ($MILLION)

TABLE 19. CANADA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 20. CANADA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 21. CANADA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 22. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 23. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 24. NORTH AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 25. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)

TABLE 26. UK ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 27. UK ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 28. UK ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 29. GERMANY ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 30. GERMANY ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 31. GERMANY ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 32. FRANCE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 33. FRANCE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 34. FRANCE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 35. REST OF EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 36. REST OF EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 37. REST OF EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 38. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 39. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 40. EUROPE ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 41. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)

TABLE 42. JAPAN ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 43. JAPAN ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 44. JAPAN ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 45. CHINA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 46. CHINA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 47. CHINA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 48. AUSTRALIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 49. AUSTRALIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 50. AUSTRALIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 51. INDIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 52. INDIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 53. INDIA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 54. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 55. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 56. REST OF ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 57. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 58. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 59. ASIA-PACIFIC ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 60. LAMEA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY COUNTRY, 2019-2027 ($MILLION)

TABLE 61. LATIN AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 62. LATIN AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 63. LATIN AMERICA ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 64. MIDDLE EAST AND AFRICAARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY TYPE, 2019-2027 ($MILLION)

TABLE 65. MIDDLE EAST AND AFRICAARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY INDICATION, 2019-2027 ($MILLION)

TABLE 66. MIDDLE EAST AND AFRICAARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY AND DEVELOPMENT , BY END USER, 2019-2027 ($MILLION)

TABLE 67. ALPHABET INC.: COMPANY SNAPSHOT

TABLE 68. ALPHABET INC.: OPERATING SEGMENTS

TABLE 69. ALPHABET INC.: PRODUCT PORTFOLIO

TABLE 70. ATOMWISE: COMPANY SNAPSHOT

TABLE 71. ATOMWISE: PRODUCT PORTFOLIO

TABLE 72. BENEVOLENT: COMPANY SNAPSHOT

TABLE 73. BENEVOLENT: PRODUCT PORTFOLIO

TABLE 74. CLOUD: COMPANY SNAPSHOT

TABLE 75. CLOUD: PRODUCT PORTFOLIO

TABLE 76. DEEP: COMPANY SNAPSHOT

TABLE 77. DEEP: PRODUCT PORTFOLIO

TABLE 78. EXSCIENTIA: COMPANY SNAPSHOT

TABLE 79. EXSCIENTIA: PRODUCT PORTFOLIO

TABLE 80. IBM CORPORATION: COMPANY SNAPSHOT

TABLE 81. IBM: OPERATING SEGMENTS

TABLE 82. IBM: PRODUCT PORTFOLIO

TABLE 83. INSILICO: COMPANY SNAPSHOT

TABLE 84. INSILICO: PRODUCT PORTFOLIO

TABLE 85. MICROSOFT CORPORATION: COMPANY SNAPSHOT

TABLE 86. MICROSOFT CORPORATION: OPERATING SEGMENTS

TABLE 87. MICROSOFT: PRODUCT PORTFOLIO

TABLE 88. NVIDIA: COMPANY SNAPSHOT

TABLE 89. NVIDIA: OPERATING SEGMENTS

TABLE 90. NVIDIA: PRODUCT PORTFOLIO